KOD
Kodiak Sciences Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kodiak Sciences Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
+3.43%
vs ±9.8% implied · ×0.35
shaded = implied · ▲▼ = realized
Kodiak Sciences Inc.
98.95
pre 98.01 −0.89%
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $776.1M | 32.23% | 0.00% |
| BlackRockindex-like | $161.1M | 6.69% | +5.08% |
| T. Rowe Price | $126.6M | 5.26% | +59.30% |
| State Streetindex-like | $94.3M | 3.91% | +7.49% |
| Goldman Sachs | $90.2M | 3.75% | +33.18% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Kodiak Sciences Inc.'s 6 closest co-movers, none share that code.
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $776.1M | 32.23% | 0.00% |
| BlackRockindex-like | $161.1M | 6.69% | +5.08% |
| T. Rowe Price | $126.6M | 5.26% | +59.30% |
| State Streetindex-like | $94.3M | 3.91% | +7.49% |
| Goldman Sachs | $90.2M | 3.75% | +33.18% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Kodiak Sciences Inc.'s 6 closest co-movers, none share that code.
Bull2
Bear1
Largest filed tie
—
Tall tick = annual report · Source: EDGAR
—
—
Expected move
Inputsspot 98.89exp Nov 20ATM strike 100ATM straddle 14.40IV 84%